Avanza Fonder Ab Bei Gene, Ltd. Transaction History
Avanza Fonder Ab
- $3.37 Trillion
- Q4 2024
A detailed history of Avanza Fonder Ab transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Avanza Fonder Ab holds 675 shares of BGNE stock, worth $135,668. This represents 0.0% of its overall portfolio holdings.
Number of Shares
675Holding current value
$135,668% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
254Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.12 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.29 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.04 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$1 Billion0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$745 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.8B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...